A Comprehensive Approach to Managing Advanced Parkinson's Disease

Title:

A Comprehensive Approach to Managing Advanced Parkinson's Disease

Topic: Neurology
Relevant Terms: Parkinson's Disease
Primary Audience: Neurologists, Nurse Practioners, and Physician Assistants in Neurology
Launch Date: 02-Aug-16
Credits: AMA PRA Category 1 Credits
Expiration Date: 02-Aug-17
Curriculum Name: A Comprehensive Approach to Managing Advanced Parkinson's Disease

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Recognize levodopa-induced motor complications of Parkinson's disease (PD) on the basis of an improved understanding of the progressive pathophysiology of the disease in the context of the long-term use of orally administered, immediate-release levodopa therapy
  2. Implement proven pharmacologic therapies to address levodopa-induced motor complications of PD and appropriately select patients who are eligible for more invasive treatments
  3. Integrate supportive care strategies (e.g., physical and occupational therapy) to complement the pharmacologic and/or surgical management of advanced PD

    Faculty

    Robert A. Hauser, MD, MBA
    Director
    USF Health Byrd Parkinson's Disease and Movement Disorders Center
    National Parkinson Foundation Center of Excellence
    Professor
    University of South Florida
    Tampa, Florida
    Kelly Tehan, PA-C
    Physician Assistant
    USF Health Byrd Parkinson's Disease and Movement Disorders Center
    National Parkinson Foundation Center of Excellence
    University of South Florida
    Tampa, Florida
    EINSTEIN PEER REVIEWER
    David M. Kaufman, MD
    Professor of Neurology and Psychiatry
    Albert Einstein College of Medicine
    Montefiore Medical Center
    Bronx, New York
     
    PHYSICIAN CONTINUING MEDICAL EDUCATION
    Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and RMEI Medical Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
     
    Credit Designation
    Albert Einstein College of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    DISCLOSURE OF CONFLICTS OF INTEREST
    The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relevant relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.

    Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. Albert Einstein College of Medicine, CCME staff, has no relevant conflicts of interest with commercial interests related directly or indirectly to this educational activity.
     
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
    • Robert A. Hauser, MD, MBA, has affiliations with Adamas Pharmaceuticals, Biotie Therapies, Cynapsus Therapeutics, ERT, Jefferies, Lundbeck, Neuropore, Neurocrine Biosciences, Sarepta Therapeutics, Teva, US WorldMeds (Consulting Fees); University of South Florida (Salary); Acadia Pharmaceuticals, Acorda, Adagio Pharmaceuticals, AstraZeneca, Biotie Therapies, Impax Pharmaceuticals, Intec, Kyowa, Lundbeck, Michael J. Fox Foundation, Pfizer, Pharma Two B, Revance Therapeutics, Sarepta Therapeutics (Clinical Research).
    • Kelly Tehan, PA-C, has no affiliations with commercial interests to disclose.
    RMEI Medical Education, LLC
    • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
    • Barbara Martin, MD, has no affiliations with commercial interests to disclose.
    • Nora Hartley has no affiliations with commercial interests to disclose.
    • Amy Reeve has no affiliations with commercial interests to disclose.
    Albert Einstein College of Medicine
    • David M. Kaufman, MD, has no affiliations with commercial interests to disclose.
    • Victor Hatcher, PhD, Associate Dean, has no affiliations with commercial interests to disclose.
     
    DISCLOSURE OF UNLABELED USE
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine, RMEI Medical Education, LLC, and AbbVie. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
     
    Estimated time to complete: 2.0 hours
    Medium: Internet

    FEE INFORMATION
    There is no fee for this educational activity.

    COMMERCIAL SUPPORT
    This activity is supported by an independent medical educational grant from AbbVie.

    HOW TO RECEIVE CREDIT
    By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 2.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity evaluation.
    Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
     
    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above